JRPIM
ALNY icon

Journey Retirement Planning & Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Journey Retirement Planning & Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-630
Closed -$251K – 139
2025
Q4 		$251K Buy
+630
New +$279K 0.05% 218

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Journey Retirement Planning & Investment Management's ALNY Position: Q1 2026 in Review

Journey Retirement Planning & Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 630 shares — an estimated $251K sold.

Journey Retirement Planning & Investment Management first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $251K in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Journey Retirement Planning & Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Journey Retirement Planning & Investment Management sold 630 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $251K.
  • Journey Retirement Planning & Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Journey Retirement Planning & Investment Management's Alnylam Pharmaceuticals position peaked at $251K in Q4 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Journey Retirement Planning & Investment Management's 13F filing for Q1 2026, filed 15 May 2026.